WO2004050023A3 - Treatment of diseases and conditions mediated by increased phosphorylation - Google Patents

Treatment of diseases and conditions mediated by increased phosphorylation Download PDF

Info

Publication number
WO2004050023A3
WO2004050023A3 PCT/US2003/037901 US0337901W WO2004050023A3 WO 2004050023 A3 WO2004050023 A3 WO 2004050023A3 US 0337901 W US0337901 W US 0337901W WO 2004050023 A3 WO2004050023 A3 WO 2004050023A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
treatment
increased phosphorylation
conditions mediated
pac
Prior art date
Application number
PCT/US2003/037901
Other languages
French (fr)
Other versions
WO2004050023A2 (en
Inventor
David Bar-Or
Original Assignee
Dmi Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020057009700A priority Critical patent/KR101188292B1/en
Priority to NZ540767A priority patent/NZ540767A/en
Application filed by Dmi Biosciences Inc filed Critical Dmi Biosciences Inc
Priority to JP2004557358A priority patent/JP5204947B2/en
Priority to EP03799853.1A priority patent/EP1572115B1/en
Priority to CA2507051A priority patent/CA2507051C/en
Priority to AU2003299568A priority patent/AU2003299568B2/en
Priority to CN2003801093164A priority patent/CN1980948B/en
Priority to BR0315942-6A priority patent/BR0315942A/en
Publication of WO2004050023A2 publication Critical patent/WO2004050023A2/en
Priority to IL168775A priority patent/IL168775A/en
Priority to HK06103092.5A priority patent/HK1083062A1/en
Publication of WO2004050023A3 publication Critical patent/WO2004050023A3/en
Priority to IL205851A priority patent/IL205851A/en
Priority to IL205852A priority patent/IL205852A/en
Priority to IL205850A priority patent/IL205850A/en
Priority to AU2010235897A priority patent/AU2010235897A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

The invention provides methods for the treatment of diseases and conditions mediated by increased phosphorylation, such as inflammation and cancer. The invention also provides methods for the inhibition of increased phosphorylation in cells, tissues and organs. The methods utilize a phosphate acceptor compound (PAC). The invention also provides products comprising a PAC.
PCT/US2003/037901 2002-11-27 2003-11-25 Treatment of diseases and conditions mediated by increased phosphorylation WO2004050023A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
CN2003801093164A CN1980948B (en) 2002-11-27 2003-11-25 Treatment of diseases and conditions mediated by increased phosphorylation
BR0315942-6A BR0315942A (en) 2002-11-27 2003-11-25 Treatment of diseases and conditions mediated by increased phosphorylation
JP2004557358A JP5204947B2 (en) 2002-11-27 2003-11-25 Use of phosphate receptor compounds and pharmaceutical compositions, skin care compositions and kits containing phosphate receptor compounds
NZ540767A NZ540767A (en) 2002-11-27 2003-11-25 Treatment of diseases and conditions mediated by increased phosphorylation
CA2507051A CA2507051C (en) 2002-11-27 2003-11-25 Treatment of diseases and conditions mediated by increased phosphorylation
AU2003299568A AU2003299568B2 (en) 2002-11-27 2003-11-25 Treatment of diseases and conditions mediated by increased phosphorylation
EP03799853.1A EP1572115B1 (en) 2002-11-27 2003-11-25 Treatment of diseases and conditions mediated by increased phosphorylation
KR1020057009700A KR101188292B1 (en) 2002-11-27 2003-11-25 Treatment of diseases and conditions mediated by increased phosphorylation
IL168775A IL168775A (en) 2002-11-27 2005-05-24 Use of an extracellular phosphate-acceptor compound for manufacture of a medicament for treating diseases and conditions mediated by increased phosphorylation
HK06103092.5A HK1083062A1 (en) 2002-11-27 2006-03-10 Treatment of diseases and conditions mediated by increased phosphorylation
IL205851A IL205851A (en) 2002-11-27 2010-05-17 Use of an extracellular phosphate acceptor compound in the manufacture of an oral care product for teeth whitening
IL205852A IL205852A (en) 2002-11-27 2010-05-17 Personal care product comprising an extracellular phosphate acceptor compound, a kit comprising same and use thereof for inhibiting a disease or a condition mediated by increased phosphorylation
IL205850A IL205850A (en) 2002-11-27 2010-05-17 Solution for inhibiting increased phosphorylation in a cell, a tissue or an organ removed from an animal
AU2010235897A AU2010235897A1 (en) 2002-11-27 2010-10-19 Treatment of diseases and conditions mediated by increased phosphorylation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42992402P 2002-11-27 2002-11-27
US60/429,924 2002-11-27

Publications (2)

Publication Number Publication Date
WO2004050023A2 WO2004050023A2 (en) 2004-06-17
WO2004050023A3 true WO2004050023A3 (en) 2007-02-15

Family

ID=32469391

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/037901 WO2004050023A2 (en) 2002-11-27 2003-11-25 Treatment of diseases and conditions mediated by increased phosphorylation

Country Status (13)

Country Link
US (3) US7982008B2 (en)
EP (1) EP1572115B1 (en)
JP (1) JP5204947B2 (en)
KR (1) KR101188292B1 (en)
CN (2) CN102266272B (en)
AU (3) AU2003299568B2 (en)
BR (1) BR0315942A (en)
CA (1) CA2507051C (en)
HK (2) HK1083062A1 (en)
IL (4) IL168775A (en)
NZ (2) NZ540767A (en)
WO (1) WO2004050023A2 (en)
ZA (1) ZA200505113B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050023A2 (en) 2002-11-27 2004-06-17 Dmi Biosciences, Inc. Treatment of diseases and conditions mediated by increased phosphorylation
EP2112920B1 (en) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US20060147507A1 (en) * 2005-01-04 2006-07-06 Marie Cammarata Hot flash treatment system
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
US20070238808A1 (en) * 2006-03-09 2007-10-11 Goldberg A J Dental materials, methods of making and using the same, and articles formed therefrom
US20070231274A1 (en) * 2006-03-28 2007-10-04 Myrex Pharmaceuticals Inc. Mouthwash and Method of Using Same for the Treatment of Mucositis or Stomatitis
CN101453993A (en) 2006-04-03 2009-06-10 伊萨·奥迪迪 Controlled release delivery device comprising an organosol coat
US10960077B2 (en) * 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
WO2008073614A2 (en) * 2006-11-02 2008-06-19 Akpharma Inc. Composition and method for enhancing skin cell growth, proliferation and repair
EP2285866A2 (en) * 2008-04-22 2011-02-23 Angiotech Pharmaceuticals, Inc. Biocompatible crosslinked hydrogels, drug-loaded hydrogels and methods of using the same
US8481006B2 (en) * 2008-04-25 2013-07-09 New Sunshine, Llc Melt formula
FR2934158B1 (en) * 2008-07-23 2012-08-17 Yvon Gauthier DERMOCOSMETIC COMPOSITION, AESTHETIC TREATMENT PROCESS FROM THE COMPOSITION, AND USE OF THE COMPOSITION FOR LIGHTENING THE PIGMENTATION OF THE SKIN.
RS55372B1 (en) 2011-04-29 2017-03-31 Moberg Pharma Ab Pharmaceutical compositions comprising a local anaesthetic such as bupivacaine for local administration to the mouth or throat
KR101822941B1 (en) * 2012-02-06 2018-01-29 엘지전자 주식회사 Air cleaning filter and method for manufacturing the same
WO2017192200A1 (en) 2016-05-05 2017-11-09 The Research Foundation For The State Unversity Of New York Compositions for treating periodontitis and dental calculus accumulation
KR102203626B1 (en) * 2018-03-22 2021-01-15 건국대학교 산학협력단 Pharmaceutical and functional food composition comprising phosvitin and lysozyme for enhancing immunity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966915A (en) * 1972-02-11 1976-06-29 Istituto Farmacologico Serono S.P.A. Treatment of heart diseases
WO1982003008A1 (en) * 1981-03-04 1982-09-16 Reynolds Eric Charles Caries inhibition
US5279814A (en) * 1990-03-09 1994-01-18 Henkel Kommanditgesellschaft Auf Aktien Oral-hygiene/dentifrice preparations which protect dental enamel

Family Cites Families (211)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US25044A (en) * 1859-08-09 Improved furnace for making iron direct from the ore
DE942643C (en) 1952-07-04 1956-05-03 Telefunken Gmbh Procedure for phase control of spatially distant cooperating transmitters, taking into account fluctuations in transit time
US3558770A (en) * 1967-09-01 1971-01-26 Kraftco Corp Wound treating composition employing an enzyme modified casein
US3995070A (en) * 1971-05-26 1976-11-30 Morinaga Milk Industry Co., Ltd. Process for preparing a casein micelle
US3901979A (en) * 1971-08-30 1975-08-26 Morinaga Milk Industry Co Ltd Process for preparing a low sodium infant formula mixture
BE795269A (en) 1972-02-11 1973-08-09 Serono Ist Farm TREATMENT OF HEART AFFECTIONS
US3941763A (en) * 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4284623A (en) * 1979-11-09 1981-08-18 Beck Lee R Method of treating inflammation using bovine milk
FR2474828B1 (en) 1980-02-01 1983-09-09 Agronomique Inst Nat Rech PROCESS FOR TREATING A CASEIN RAW MATERIAL CONTAINING BIVALENT CATION PHOSPHOCASEINATES, PRODUCTS OBTAINED AND APPLICATION
US5334408A (en) * 1980-02-01 1994-08-02 Institut National De La Recherche Agronomique Nutrient composition containing non-phosphorylated peptides from casin-based material
FR2474829B1 (en) 1980-02-01 1983-09-09 Agronomique Inst Nat Rech PROCESS FOR THE TREATMENT OF A CASEIN MATERIAL CONTAINING PHOSPHOCASEINATES OF MONOVALENT CATIONS OR DERIVATIVES THEREOF, PRODUCTS OBTAINED AND APPLICATIONS
AU527371B2 (en) 1980-09-16 1983-03-03 Torii & Co., Ltd. Amidine
US4419369A (en) 1980-09-22 1983-12-06 Baylor College Of Medicine Protein mineral dietary module
FR2491334A1 (en) * 1980-10-03 1982-04-09 Inst Nat Sante Rech Med NOVEL BIOLOGICALLY ACTIVE SUBSTANCES, THEIR OBTAINMENT FROM HUMAN CASEIN AND COMPOSITIONS CONTAINING THEM
US5130123A (en) * 1981-03-04 1992-07-14 The University Of Melbourne Dentifrice
DE3117571A1 (en) * 1981-05-04 1982-11-18 Licentia Patent-Verwaltungs-Gmbh, 6000 Frankfurt LUMINESCENCE SEMICONDUCTOR COMPONENT
US4612122A (en) * 1981-06-29 1986-09-16 Clara Ambrus Removing heavy metal ions from blood
US4847283A (en) 1983-01-10 1989-07-11 Harendza Harinxma Alfred J Ointment and method for treating skin lesions due to herpes virus
SE8302789D0 (en) 1983-05-18 1983-05-18 Andersson A E Bror ORAL DENTAL COMPOSITION
FR2565985B1 (en) 1984-06-19 1987-09-25 Rhone Poulenc Sante NOVEL BIOLOGICALLY ACTIVE SUBSTANCES OBTAINED FROM BOVINE CASEIN, THEIR PREPARATION PROCESS AND THE COMPOSITIONS CONTAINING THEM
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
US4879283A (en) 1985-10-03 1989-11-07 Wisconsin Alumni Research Foundation Solution for the preservation of organs
US4768824A (en) * 1986-10-16 1988-09-06 Garbis Andonian Truck bed covering
US5180578A (en) 1987-01-30 1993-01-19 Colgate-Palmolive Company Antibacterial antiplaque anticalculus oral composition
US5294431A (en) 1987-01-30 1994-03-15 Colgate-Palmolive Co. Antibacterial antiplaque oral composition mouthwash or liquid dentifrice
US5032374A (en) * 1987-10-22 1991-07-16 Hughes Aircraft Company Preparation of metal sulfides
US5709873A (en) * 1988-02-26 1998-01-20 Niels Bukh A/S Method of treating conditions of teeth and their supporting tissue
US5187547A (en) * 1988-05-18 1993-02-16 Sanyo Electric Co., Ltd. Light emitting diode device and method for producing same
US6020015A (en) * 1988-09-22 2000-02-01 Gaull; Gerald E. Infant formula compositions and nutrition containing genetically engineered human milk proteins
US5032384A (en) 1989-01-27 1991-07-16 Block Drug Company, Inc. Compositions and method for the treatment of disease
DE59007006D1 (en) 1989-01-27 1994-10-13 Siemens Ag Message processing device to be connected inductively.
EP0400176B1 (en) * 1989-05-31 2000-07-26 Osram Opto Semiconductors GmbH & Co. OHG Method to mount a surface-mountable optical element
EP0400175B1 (en) * 1989-05-31 1994-12-28 Siemens Aktiengesellschaft Surface-mountable optical element
JPH0343750U (en) * 1989-09-04 1991-04-24
US5043183A (en) 1989-09-13 1991-08-27 Cambridge Research Laboratories, Inc. Oral rinse and method for plaque removal
US5198220A (en) * 1989-11-17 1993-03-30 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
US5019746A (en) * 1989-12-04 1991-05-28 Hewlett-Packard Company Prefabricated wire leadframe for optoelectronic devices
US5795611A (en) * 1989-12-20 1998-08-18 Slattery; Charles W. Human infant formulas containing recombinant human alpha-lactalbumin and beta-casein
US5092897A (en) * 1990-03-15 1992-03-03 Forte Mark R Implantable acetabular prosthetic hip joint with universal adjustability
US5385915A (en) * 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
US6319522B1 (en) 1990-07-13 2001-11-20 Gropep Limited Growth-promoting agent
US5068118A (en) 1990-07-25 1991-11-26 Kraft General Foods, Inc. Method of making simulated cheese containing casein materials
US5189046A (en) * 1990-08-14 1993-02-23 Nova Pharmaceutical Corporation Protein kinase C modulators
US5571786A (en) 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
US5037634A (en) 1990-08-16 1991-08-06 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Oral compositions containing stabilized copper
EP0475779A1 (en) * 1990-09-14 1992-03-18 Vittal Mallya Scientific Research Foundation Process for the separation of proteins, polypeptides or metals using immobilized, optionally modified, phosvitin
ES2071336T3 (en) * 1990-10-25 1995-06-16 Boots Co Plc Mouthwash
US5119174A (en) * 1990-10-26 1992-06-02 Chen Der Jong Light emitting diode display with PCB base
US5204370A (en) * 1990-11-05 1993-04-20 Sphinx Pharmaceuticals Corporation Bis-(hydroxyalkylamino)-anthraquinone inhibitors of protein kinase C
AU637014B2 (en) * 1990-11-02 1993-05-13 Sphinx Pharmaceuticals Corporation Bis-(hydroxyalkylamino)-anthraquinone inhibitors of protein kinase c
US5141957A (en) * 1990-11-02 1992-08-25 Sphinx Pharmaceuticals Corporation 1,4-bis-(amino-hydroxyalkylamino)-anthraquinones for inhibiting protein kinase c
JP2744350B2 (en) * 1990-11-22 1998-04-28 キヤノン株式会社 Semiconductor substrate and method of manufacturing the same
US5221641A (en) * 1991-06-21 1993-06-22 Rohm Co., Ltd. Process for making light emitting diodes
EP0525388B1 (en) * 1991-07-01 1995-09-20 Gerhard Dr. Gergely Suckable or chewable tablet
JPH0525032A (en) * 1991-07-22 1993-02-02 Pola Chem Ind Inc Cosmetic
WO1993004171A1 (en) 1991-08-19 1993-03-04 Symbicom Aktiebolag Human beta-casein, process for producing it and use thereof
US5216014A (en) * 1991-09-10 1993-06-01 Sphinx Pharmaceuticals Corporation Furo-coumarinsulfonamides as protein kinase C inhibitors
US5286479A (en) * 1991-12-10 1994-02-15 The Dow Chemical Company Oral compositions for suppressing mouth odors
US5270310A (en) 1991-12-13 1993-12-14 Sphinx Pharmaceuticals Corporation N-aminoalkyl amide inhibitors of protein kinase C
DK8892D0 (en) * 1992-01-23 1992-01-23 Symbicom Ab HUMANT PROTEING
US5298237A (en) 1992-01-24 1994-03-29 The Trustees Of Columbia University In The City Of New York Gel composition for reduction of gingival inflammation and retardation of dental plaque
DE4242842C2 (en) * 1992-02-14 1999-11-04 Sharp Kk Light-emitting component for surface mounting and method for its production
US5280038A (en) * 1992-03-13 1994-01-18 Virginia Commonwealth University Histidine as a protective agent in cardiac surgery and myocardial ischemic syndrome
US5186479A (en) * 1992-03-20 1993-02-16 Flowers Henry C Multi-function cart
JPH05275785A (en) * 1992-03-28 1993-10-22 Sony Corp Laser light generating optical device
US5785887A (en) 1992-04-17 1998-07-28 Colgate-Palmolive Company Peroxygen bleach composition
US5266817A (en) * 1992-05-18 1993-11-30 Lin Paul Y S Package structure of multi-chip light emitting diode
US5855872A (en) * 1992-06-22 1999-01-05 Libin; Barry M. Compositions for treating herpes simplex virus infections
US5292527A (en) 1992-07-02 1994-03-08 Bausch & Lomb Incorporated Non-alcoholic aqueous mouthwash
US6544502B2 (en) * 1992-09-11 2003-04-08 Wasatch Pharmaceutical Inc. Skin treatment with a water soluble antibiotic dissolved in an electrolyzed water
US5432178A (en) 1992-09-18 1995-07-11 Ono Pharmaceutical Co., Ltd. Amidinophenol derivatives
WO1994009370A1 (en) 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Release of alzheimer amyloid precursor stimulated by activation of muscarinic acetylcholine receptors
US5242910A (en) * 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
US5292737A (en) * 1992-10-23 1994-03-08 Sphinx Pharmaceuticals Corporation N,N'-bis(sulfonamido)-2-amino-4-iminonaphthalen-1-ones and N,N'-bis(amido)-2-amino-4-iminonaphthalen-1-ones
GEP20002228B (en) 1992-10-28 2000-09-25 Den Mat Corp Antibacterial Mouthwash
US5302375A (en) * 1992-11-19 1994-04-12 Colgate-Palmolive Company Oral composition having improved tooth whitening effect
US5575654A (en) 1992-11-24 1996-11-19 Fontenot; Mark G. Apparatus and method for lightening teeth
US5980249A (en) 1992-11-24 1999-11-09 Folh, Llc Method and device for treatment of dentition
US5863202A (en) 1992-11-24 1999-01-26 Fontenot; Mark G. Device and method for treatment of dentition
US5999151A (en) * 1992-12-24 1999-12-07 Michael; Robert Pixel, video display screen and power delivery
US5861156A (en) * 1993-01-08 1999-01-19 Creative Biomolecules Methods of delivering agents to target cells
US5534718A (en) * 1993-04-12 1996-07-09 Hsi-Huang Lin LED package structure of LED display
US5340993A (en) * 1993-04-30 1994-08-23 Motorola, Inc. Optocoupler package wth integral voltage isolation barrier
US5405742A (en) * 1993-07-16 1995-04-11 Cyromedical Sciences, Inc. Solutions for tissue preservation and bloodless surgery and methods using same
US5753227A (en) * 1993-07-23 1998-05-19 Strahilevitz; Meir Extracorporeal affinity adsorption methods for the treatment of atherosclerosis, cancer, degenerative and autoimmune diseases
IT1265106B1 (en) * 1993-07-23 1996-10-30 Solari Udine Spa OPTICAL SYSTEM FOR LIGHT-EMITTING DIODES
US5476647A (en) 1993-09-13 1995-12-19 American Dental Association Health Foundation Complex calcium and fluoride containing mouth rinses, dentifrices, and chewable tablets
EP0660467B1 (en) * 1993-12-22 1997-03-19 Siemens Aktiengesellschaft Optoelectronical element and method of making the same
FR2714369B1 (en) 1993-12-29 1996-01-26 Rhone Poulenc Chimie Abrasive silicas for toothpaste compositions.
US5514627A (en) * 1994-01-24 1996-05-07 Hewlett-Packard Company Method and apparatus for improving the performance of light emitting diodes
KR100309623B1 (en) * 1994-02-28 2002-04-24 사토 게니치로 Light emitting diode lamps and matrix indicators using them
US5874080A (en) * 1994-03-03 1999-02-23 Genentech, Inc. Anti-IL-8 monoclonal antibodies for treatment of asthma
JPH07281619A (en) * 1994-04-04 1995-10-27 Rohm Co Ltd Led lamp and mounting structure of the lamp on substrate
AU2204995A (en) 1994-04-07 1995-10-30 Jon L. Richter Oral rinse and method of treating halitosis
CA2143037C (en) 1994-05-02 2002-04-30 Atma Chaudhari Alcohol free mouthwash
US5583221A (en) 1994-05-04 1996-12-10 Eli Lilly And Company Substituted fused and bridged bicyclic compounds as therapeutic agents
JP2994219B2 (en) * 1994-05-24 1999-12-27 シャープ株式会社 Method for manufacturing semiconductor device
CA2190609A1 (en) 1994-05-26 1995-12-07 Pradip Mukerji Inhibition of infection of mammalian cells by respiratory syncytial virus
RU94020019A (en) 1994-05-31 1996-11-27 Акционерное общество закрытого типа "ОСТИМ" Medicinal film for parodontitis treatment
CN1127620A (en) 1994-07-10 1996-07-31 王海生 Combined high-efficiency tooth paste
WO1996002275A1 (en) 1994-07-20 1996-02-01 Toyama Chemical Co., Ltd. Sustained-release oral ointment
US5432198A (en) * 1994-08-18 1995-07-11 Sphinx Pharmaceuticals Corporation Vicinal-substituted carbocyclic compounds as therapeutic agents
JP3417079B2 (en) * 1994-08-31 2003-06-16 ソニー株式会社 Method for manufacturing semiconductor device
US5578576A (en) 1994-09-02 1996-11-26 Dalhousie University Method and composition for treating intestinal wounds or ulcers
JPH10505831A (en) 1994-09-15 1998-06-09 ザ、プロクター、エンド、ギャンブル、カンパニー Oral composition
US5712250A (en) 1994-09-16 1998-01-27 Abbott Laboratories Product for inhibition of human rotavirus infection
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5942254A (en) * 1995-02-27 1999-08-24 Abbott Laboratories Phosphorylated recombinant human β-casein expressed in a bacterial system
DE19508222C1 (en) * 1995-03-08 1996-06-05 Siemens Ag Opto-electronic converter
EP0748591B1 (en) * 1995-06-16 2001-10-17 Societe Des Produits Nestle S.A. Fluorinated micellar casein
US5869095A (en) * 1995-07-31 1999-02-09 Gerhard Gergely Chewable tablet with an effervescent action
ES2153122T3 (en) * 1995-08-08 2001-02-16 Nutricia Nv PROTEIC COMPOSITION.
US6068829A (en) 1995-09-11 2000-05-30 The Burnham Institute Method of identifying molecules that home to a selected organ in vivo
US5622699A (en) 1995-09-11 1997-04-22 La Jolla Cancer Research Foundation Method of identifying molecules that home to a selected organ in vivo
ATE232715T1 (en) 1995-09-25 2003-03-15 Robert Eric Montgomery TOOTH WHITENING COMPOSITIONS
DE19535777A1 (en) * 1995-09-26 1997-03-27 Siemens Ag Optoelectronic semiconductor component and method for producing it
TW469135B (en) 1995-10-03 2001-12-21 Chugai Pharmaceutical Co Ltd Chewable tablet
US5786335A (en) * 1995-11-06 1998-07-28 Warner-Lambert Company Sulfhydryl containing peptides for treating vascular disease
EP0862450A2 (en) 1995-11-06 1998-09-09 Abbott Laboratories A method for inhibiting attachment of h. influenzae to human cells using phosphorylated recombinant human beta-casein
DE19621124A1 (en) * 1996-05-24 1997-11-27 Siemens Ag Optoelectronic converter and its manufacturing process
DE69724986T2 (en) 1996-06-07 2004-07-15 Hercules Inc., Wilmington TOOTHPASES CONTAINING CARBOXYMETHYLCELLULOSE FLUIDIZED SUSPENSIONS
DE19638667C2 (en) * 1996-09-20 2001-05-17 Osram Opto Semiconductors Gmbh Mixed-color light-emitting semiconductor component with luminescence conversion element
US5925898A (en) * 1996-07-18 1999-07-20 Siemens Aktiengesellschaft Optoelectronic transducer and production methods
JP3504079B2 (en) * 1996-08-31 2004-03-08 株式会社東芝 Method for manufacturing semiconductor light emitting diode device
US5916548A (en) 1996-09-04 1999-06-29 The Procter & Gamble Company Personal care compositions
DE19649650B4 (en) * 1996-11-29 2005-02-24 Siemens Ag Surface-mountable radiation-emitting semiconductor component
US6147080A (en) 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US5945418A (en) * 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US5858332A (en) * 1997-01-10 1999-01-12 Ultradent Products, Inc. Dental bleaching compositions with high concentrations of hydrogen peroxide
US6391283B1 (en) 1997-01-10 2002-05-21 Ultradent Products, Inc. Methods and apparatus for activating dental compositions
US6054716A (en) * 1997-01-10 2000-04-25 Rohm Co., Ltd. Semiconductor light emitting device having a protecting device
CA2223198A1 (en) 1997-01-14 1998-07-14 Societe Des Produits Nestle S.A. Composition and method for treatment of inflammatory conditions of the gastro-intestinal tract
US6321909B1 (en) 1997-02-13 2001-11-27 Sky High, Llc System for storing polyethylene glycol solutions
US6268194B1 (en) * 1997-02-25 2001-07-31 The Regents Of The University Of California IKB kinase and methods of using same
JP3572924B2 (en) * 1997-03-06 2004-10-06 松下電器産業株式会社 Light emitting device and recording device using the same
US5865529A (en) * 1997-03-10 1999-02-02 Yan; Ellis Light emitting diode lamp having a spherical radiating pattern
JPH11103097A (en) * 1997-07-30 1999-04-13 Rohm Co Ltd Semiconductor light emitting element
AUPO566297A0 (en) * 1997-03-13 1997-04-10 University Of Melbourne, The Calcium phosphopeptide complexes
US5922331A (en) * 1997-03-26 1999-07-13 Chanel, Inc. Skin cream composition
US5902786A (en) * 1997-04-15 1999-05-11 Advanced Viral Research Corp. Treatment of basal cell carcinoma with product R, a peptide-nucleic acid preparation
US5879691A (en) * 1997-06-06 1999-03-09 The Procter & Gamble Company Delivery system for a tooth whitener using a strip of material having low flexural stiffness
US6503483B2 (en) * 1997-06-12 2003-01-07 C.S. Bioscience, Inc. Dental formulation
US6026829A (en) * 1997-06-17 2000-02-22 Gillette Canada Inc. Dental floss containing encapsulating flavoring material
US5906811A (en) 1997-06-27 1999-05-25 Thione International, Inc. Intra-oral antioxidant preparations
US6093742A (en) * 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
US6102050A (en) * 1997-07-10 2000-08-15 Marcon; Robert Victor Remedial dental floss
CA2239400C (en) 1997-07-10 2003-09-09 Robert V. Marcon Medicated dental floss
DE59712198D1 (en) 1997-07-10 2005-03-17 Gergely Dr & Co Soluble, gum-coated, coated chewable tablet
JP3663281B2 (en) * 1997-07-15 2005-06-22 ローム株式会社 Semiconductor light emitting device
US6197331B1 (en) 1997-07-24 2001-03-06 Perio Products Ltd. Pharmaceutical oral patch for controlled release of pharmaceutical agents in the oral cavity
US5962971A (en) * 1997-08-29 1999-10-05 Chen; Hsing LED structure with ultraviolet-light emission chip and multilayered resins to generate various colored lights
US6242253B1 (en) * 1997-10-09 2001-06-05 Regents Of The University Of California IkB kinase, subunits thereof, and methods of using same
AU753587B2 (en) 1997-11-14 2002-10-24 Johnson & Johnson Consumer Companies, Inc. Highly flavored dental floss
JPH11163419A (en) * 1997-11-26 1999-06-18 Rohm Co Ltd Light-emitting device
US5932580A (en) * 1997-12-01 1999-08-03 Yissum Research And Development Company Of The Hebrew University Of Jerusalem PDGF receptor kinase inhibitory compounds their preparation and compositions
US6228347B1 (en) 1997-12-01 2001-05-08 Thione International, Inc. Antioxidant gel for gingival conditions
US6184544B1 (en) * 1998-01-29 2001-02-06 Rohm Co., Ltd. Semiconductor light emitting device with light reflective current diffusion layer
US6291514B1 (en) 1998-02-09 2001-09-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
US6251372B1 (en) 1998-02-27 2001-06-26 The Procter & Gamble Company Oral care compositions comprising chlorite and methods
US5876701A (en) * 1998-02-27 1999-03-02 Colgate Palmolive Company Striped toothpaste stable to color bleeding
US6350438B1 (en) 1998-02-27 2002-02-26 The Procter & Gamble Company Oral care compositions comprising chlorite and methods
US6066673A (en) * 1998-03-12 2000-05-23 The Procter & Gamble Company Enzyme inhibitors
US6232287B1 (en) * 1998-03-13 2001-05-15 The Burnham Institute Molecules that home to various selected organs or tissues
JP3078257B2 (en) * 1998-04-15 2000-08-21 ティーディーケイ株式会社 Organic EL display device and manufacturing method thereof
US6169295B1 (en) * 1998-05-29 2001-01-02 Maxim Integrated Products, Inc. Infrared transceiver module and method for making same
US5976507A (en) 1998-06-04 1999-11-02 Colgate Palmolive Company Dentrifice composition containing encapsulated reactive ingredients
JP2002517486A (en) 1998-06-12 2002-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド inhibitors of p38
US6045780A (en) * 1998-06-22 2000-04-04 Shemberg Marketing Corporation Toothpaste composition
US6071412A (en) * 1998-07-27 2000-06-06 Hemex, Inc. Extracorporeal device containing immobilized chelator on silica substrate and use thereof
DE19836338A1 (en) * 1998-08-11 2000-02-24 Nutricia Nv Dephosphorylated protein component useful in dietetic foods for subjects with gastrointenstinal motility disorders
US6270790B1 (en) 1998-08-18 2001-08-07 Mxneil-Ppc, Inc. Soft, convex shaped chewable tablets having reduced friability
US5914501A (en) * 1998-08-27 1999-06-22 Hewlett-Packard Company Light emitting diode assembly having integrated electrostatic discharge protection
US6325788B1 (en) * 1998-09-16 2001-12-04 Mckay Douglas William Treatment of wound or joint for relief of pain and promotion of healing
US6060078A (en) * 1998-09-28 2000-05-09 Sae Han Pharm Co., Ltd. Chewable tablet and process for preparation thereof
US6296868B1 (en) 1998-11-19 2001-10-02 Advanced Technology Pharmaceuticals Corporation Chewable tablets containing mannitol and aspartame
US6270781B1 (en) * 1999-01-08 2001-08-07 Maxim Pharmaceuticals, Inc. Method and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors
US6383790B1 (en) 1999-01-11 2002-05-07 Princeton University High affinity protein kinase inhibitors
US6155699A (en) * 1999-03-15 2000-12-05 Agilent Technologies, Inc. Efficient phosphor-conversion led structure
GB9923048D0 (en) 1999-09-29 1999-12-01 Nestle Sa Composition comprising casein protein and whey protein
JP2001017122A (en) 1999-07-12 2001-01-23 Taiyo Kagaku Co Ltd Food for preventing inflammation of digestive system
US20030158111A1 (en) 1999-10-01 2003-08-21 David Bar-Or Methods and products for oral care
US20030130185A1 (en) * 2000-09-29 2003-07-10 David Bar-Or Metal-binding compounds and uses therefor
KR20020057966A (en) 1999-10-01 2002-07-12 디엠아이 바이오사이언시스, 인크 Metal-binding compounds and uses therefor
US6225139B1 (en) * 2000-01-24 2001-05-01 Chan Tsung-Wen Manufacturing method of an led of a type of round concave cup with a flat bottom
US6403533B2 (en) * 2000-01-27 2002-06-11 Rohm And Haas Company Stabilized microbicide formulation
IL134830A0 (en) * 2000-03-01 2001-05-20 Chay 13 Medical Res Group N V Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
US6835383B2 (en) 2000-03-23 2004-12-28 City Of Hope Protein kinase deficient, immunologically active CMVpp65 mutants
AU2001263449A1 (en) * 2000-05-24 2001-12-03 Third Wave Technologies, Inc Detection of RNA
US6254857B1 (en) 2000-05-24 2001-07-03 Colgate-Palmolive Company Effervescent whitening dentifrice having oxygen-derived sensory signal
JP2001346588A (en) * 2000-06-08 2001-12-18 Igaku Seibutsugaku Kenkyusho:Kk Protein inhibiting human chk2-phosphorylase activity
AU2001268525A1 (en) * 2000-06-15 2001-12-24 Incyte Genomics, Inc. Human kinases
GB0016189D0 (en) 2000-06-30 2000-08-23 Pepsyn Ltd Cosmetic composition
US6290935B1 (en) 2000-07-21 2001-09-18 Colgate-Palmolive Company Dual component oral composition having accelerated tooth whitening effect
DK1311269T3 (en) * 2000-08-04 2012-03-26 Dmi Biosciences Inc PROCEDURE FOR USING DIKETOPIPERAZINES AND COMPOSITION CONTAINING THEM
PT1313440E (en) 2000-08-16 2008-10-22 Acologix Inc Dental products comprising bone growth enhancing peptide
AU2002236499A8 (en) 2000-11-30 2009-12-03 Uab Research Foundation Receptor-mediated uptake of peptides that bind the human transferrin receptor
AU2002321985A1 (en) * 2001-01-18 2002-11-18 Incyte Genomics, Inc. Kinases and phosphatases
AU2002255540A1 (en) 2001-02-13 2002-08-28 Dmi Biosciences, Inc. Metal-binding compounds and uses therefor
CN1265792C (en) * 2001-03-08 2006-07-26 肯塔基大学研究基金会 Method for increasing leptin levels using nicotinic acid compounds
US6419906B1 (en) * 2001-03-12 2002-07-16 Colgate Palmolive Company Strip for whitening tooth surfaces
GB0116509D0 (en) * 2001-07-06 2001-08-29 Hannah Res Inst The Methods of extracting casein fractions from milk and caseinates and production of novel products
US20030026794A1 (en) * 2001-07-31 2003-02-06 Howard Fein Selective enzyme treatment of skin conditions
US7200251B2 (en) * 2001-09-28 2007-04-03 The University Of North Carolina Methods and systems for modeling objects and object image data using medial atoms
DE10149668A1 (en) 2001-10-09 2003-04-10 Numico Res B V New insulin mimetic amino acid sequences, known as exsulins, useful for e.g. treating hyperinsulinemia, diabetes mellitus, autoimmune diseases or neurodegenerative diseases
US6960201B2 (en) * 2002-02-11 2005-11-01 Quanticum, Llc Method for the prevention and treatment of skin and nail infections
US6974805B2 (en) * 2002-08-01 2005-12-13 Min Hu Configuration of glycosaminoglycans
WO2004050023A2 (en) 2002-11-27 2004-06-17 Dmi Biosciences, Inc. Treatment of diseases and conditions mediated by increased phosphorylation
WO2006108417A2 (en) * 2005-04-11 2006-10-19 Natimmune A/S Mannan-binding lectin (mbl) in the treatment of immunocompromised conditions associated with cancer
EP1888081B1 (en) 2005-05-23 2016-12-28 Massachusetts Institute of Technology Compositions containing pufa and methods of use thereof
US20090008287A1 (en) 2007-07-03 2009-01-08 Trio Child, Llc Packaged Infant Care Products
WO2009113579A1 (en) * 2008-03-11 2009-09-17 学校法人埼玉医科大学 Double-stranded nucleic acid molecule suitable for prevention or treatment of cancer, cancer cell proliferation inhibitor, and pharmaceutical preparation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966915A (en) * 1972-02-11 1976-06-29 Istituto Farmacologico Serono S.P.A. Treatment of heart diseases
WO1982003008A1 (en) * 1981-03-04 1982-09-16 Reynolds Eric Charles Caries inhibition
US5279814A (en) * 1990-03-09 1994-01-18 Henkel Kommanditgesellschaft Auf Aktien Oral-hygiene/dentifrice preparations which protect dental enamel

Also Published As

Publication number Publication date
US8507651B2 (en) 2013-08-13
JP5204947B2 (en) 2013-06-05
IL205850A (en) 2016-04-21
EP1572115B1 (en) 2015-01-21
US7982008B2 (en) 2011-07-19
AU2003299568A1 (en) 2004-06-23
CA2507051A1 (en) 2004-06-17
CN102266272B (en) 2012-12-26
AU2010235897A1 (en) 2010-11-11
US20040220087A1 (en) 2004-11-04
NZ574520A (en) 2011-02-25
IL205852A (en) 2016-08-31
CN102266272A (en) 2011-12-07
ZA200505113B (en) 2006-12-27
AU2013205973A1 (en) 2013-06-06
EP1572115A2 (en) 2005-09-14
BR0315942A (en) 2005-10-04
KR20050094398A (en) 2005-09-27
IL205851A (en) 2015-06-30
CA2507051C (en) 2015-04-07
US20110237492A1 (en) 2011-09-29
US20110230417A1 (en) 2011-09-22
WO2004050023A2 (en) 2004-06-17
EP1572115A4 (en) 2009-11-25
HK1083062A1 (en) 2006-06-23
HK1164694A1 (en) 2012-09-28
CN1980948A (en) 2007-06-13
AU2003299568B2 (en) 2010-07-22
KR101188292B1 (en) 2012-10-09
CN1980948B (en) 2011-08-10
IL168775A (en) 2015-02-26
NZ540767A (en) 2009-03-31
JP2007521223A (en) 2007-08-02

Similar Documents

Publication Publication Date Title
WO2004050023A3 (en) Treatment of diseases and conditions mediated by increased phosphorylation
WO2007134678A3 (en) Triazole derivatives ii
WO2003101444A8 (en) Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
EP1140840A4 (en) -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2004113277A8 (en) Methods and compositions for treating amyloid-related diseases
WO2008019025A3 (en) Isoform-selective hdac inhibitors
JO2373B1 (en) W-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors
AU2003267203A1 (en) Method for administering thermotherapy to prevent the growth of tumors
NZ506329A (en) Inhibitors of phospholipase enzymes
WO2009010139A3 (en) Quinazolinamide derivatives
WO2004053087A3 (en) Nf-κb inhibitors
WO2004060890A8 (en) 2-oxopyridin-3-yl thia (di) azole derivates for use in the treatment of cell proliferation and apoptosis related diseases
WO2010042489A3 (en) Aminoquinoline derived heat shock protein 90 inhibitors, methods of preparing same, and methods for their use
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
AU1044500A (en) Imidazonaphthyridines
AU2001292579A1 (en) Methods and compounds for treating proliferative diseases
WO2003039545A3 (en) Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers
WO2006102375A3 (en) Methods for avoiding edema in the treatment or prevention of pparϝ-responsive diseases, including cancer
WO2004043379A3 (en) Chemical compounds
WO2005000858A3 (en) Bisphosphonate complexes
AU7520898A (en) Tetrahydropyrido compounds
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
WO2005081972A3 (en) Maleiimide anti-tumor phosphatase inhibitors
WO2008072952A3 (en) Anti-inflammatory compounds containing compositions for treatment of cancer
WO2006091544A3 (en) Methods and compositions for modulating calcium channels

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 168775

Country of ref document: IL

Ref document number: 2507051

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004557358

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020057009700

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003799853

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 540767

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003299568

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005/05113

Country of ref document: ZA

Ref document number: 200505113

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2846/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 20038A93164

Country of ref document: CN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2003799853

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057009700

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0315942

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 205850

Country of ref document: IL

Ref document number: 205851

Country of ref document: IL

Ref document number: 205852

Country of ref document: IL